Os et thérapies moléculaires ciblées: Nouveaux agents

Claire Barth; Christophe Massard; Stéphane Vignot

doi:10.1684/met.2014.0447

Os et thérapies moléculaires ciblées: Nouveaux agents

Claire Barth, Christophe Massard, Stéphane Vignot

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.

Titre traduit de la contribution	Bone targeted therapies: New agents
langue originale	Français
Pages (de - à)	118-124
Nombre de pages	7
journal	Medecine Therapeutique
Volume	20
Numéro de publication	2
Les DOIs	https://doi.org/10.1684/met.2014.0447
état	Publié - 1 janv. 2014

mots-clés

Bone targeted therapies

Accès au document

10.1684/met.2014.0447

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{3f51af7bb79544df86544740e3f39ae2,

title = "Os et th{\'e}rapies mol{\'e}culaires cibl{\'e}es: Nouveaux agents",

abstract = "The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.",

keywords = "Bone targeted therapies",

author = "Claire Barth and Christophe Massard and St{\'e}phane Vignot",

year = "2014",

month = jan,

day = "1",

doi = "10.1684/met.2014.0447",

language = "Fran{\c c}ais",

volume = "20",

pages = "118--124",

journal = "Medecine Therapeutique",

issn = "1264-6520",

number = "2",

}

TY - JOUR

T1 - Os et thérapies moléculaires ciblées

T2 - Nouveaux agents

AU - Barth, Claire

AU - Massard, Christophe

AU - Vignot, Stéphane

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.

AB - The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.

KW - Bone targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84906280405&partnerID=8YFLogxK

U2 - 10.1684/met.2014.0447

DO - 10.1684/met.2014.0447

M3 - Article

AN - SCOPUS:84906280405

SN - 1264-6520

VL - 20

SP - 118

EP - 124

JO - Medecine Therapeutique

JF - Medecine Therapeutique

IS - 2

ER -